Answers are grounded in this paper and cite their sources.
In this cross-sectional study, US DOD rates entered a new wave of sustained deceleration in 2023 after 2 decades of increase. This shift may reflect changes in drug markets, treatment access, harm reduction efforts, and population-level risk. Although the decline is encouraging, persistent disparities highlight the need for targeted interventions and improved understanding of the underlying drivers.
No takes yet. Share an insight, caveat, or question.
Post et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: